Laria Antonella, Lurati Alfredo Maria, Re Katia Angela, Marrazza Maria Grazia, Mazzocchi Daniela, Farina Alberto, Scarpellini Magda
Department of Rheumatology, Fornaroli Hospital, Magenta, Milan, Italy.
Medical Affairs Department, Italfarmaco S.p.A., Cinisello Balsamo, Milan, Italy.
Patient Relat Outcome Meas. 2015 May 19;6:139-44. doi: 10.2147/PROM.S81473. eCollection 2015.
Administration of intravenous iloprost - a first-line European League Against Rheumatism (EULAR)-recommended choice for the treatment of scleroderma (SSc)-related digital vasculopathy - requires repeated treatment cycles of 6 hours per day in a hospital setting. During the infusion, patient mobility is considerably restricted due to the size and fixity of traditional syringe pumps. The aim of this study was to evaluate the satisfaction level of patients and nurses, after the introduction of a new portable syringe pump (Infonde(®), Italfarmaco S.p.A., Milan, Italy) at the Department of Rheumatology, Magenta Hospital, Milan, Italy.
Thirty-four consecutive SSc patients receiving stable therapy with iloprost, previously administered with a fixed pump, were treated using the portable Infonde(®) pump. Patients (n=34) and nurses (n=4) were asked to answer a nine- and six-item questionnaire, respectively, to assess the satisfaction of the administration comparing the new device versus the previous one. The health care staff of the ward developed the questionnaire, and the response scores ranged from 0 (fixed device better) to 10 (portable device better); thus a score >5 indicates a preference for Infonde(®).
Patients' answers indicated a preference towards the new portable syringe pump, versus the previous fixed pump. Questionnaires administered to patients generated a total of 306 responses, with over 95% of the responses in the range 8-10, of which 89% had a score equal to 10. The responses of nurses showed a score equal to 10 in 100% cases. No significant adverse events were recorded, indicating no change in the tolerability profile of the drug.
Iloprost administration with Infonde(®) pump was preferred by both patients and health care professionals, and was well tolerated. The possibility to perform daily activities and the freedom of movement suggest a positive impact of Infonde(®) on the treatment, with a potential favorable effect on the quality of life of patients during the many hours spent receiving the infusion.
静脉输注伊洛前列素——欧洲抗风湿病联盟（EULAR）推荐的治疗硬皮病（SSc）相关指端血管病变的一线用药——需要在医院环境中每天进行6小时的重复治疗周期。在输注过程中，由于传统注射泵的尺寸和固定性，患者的活动受到很大限制。本研究的目的是评估在意大利米兰马真塔医院风湿病科引入新型便携式注射泵（Infonde®，意大利伊塔法马科股份公司，米兰，意大利）后患者和护士的满意度。
34例接受伊洛前列素稳定治疗且之前使用固定泵给药的连续性SSc患者使用便携式Infonde®泵进行治疗。分别要求患者（n = 34）和护士（n = 4）回答一份9项和6项问卷，以评估使用新设备与之前设备相比给药的满意度。病房医护人员编制了问卷，回答分数范围为0（固定设备更好）至10（便携式设备更好）；因此，分数>5表示对Infonde®的偏好。
患者的回答表明，与之前的固定泵相比，他们更喜欢新型便携式注射泵。向患者发放的问卷共收到306份回答，超过95%的回答在8 - 10分范围内，其中89%的分数为10分。护士的回答在100%的情况下分数为10分。未记录到显著不良事件，表明药物的耐受性没有变化。
患者和医护人员都更喜欢使用Infonde®泵输注伊洛前列素，且耐受性良好。进行日常活动的可能性和行动自由表明Infonde®对治疗有积极影响，对患者在接受输液的数小时内的生活质量可能有有利影响。
